NCT07032727招募中2 期
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 68
- 试验地点
- 1
- 主要终点
- Safety and adverse events (AEs)
研究概览
简要总结
To learn about the safety and tolerability of study drug combinations in patients with relapsed/refractory, IDH1-mutated myeloid malignancies with a co-signaling mutation.
详细描述
Primary Objectives
- To determine the safety and tolerability of olutasidenib in combination with cladribine + LDAC ± venetoclax (Arm 1), gilteritinib ± venetoclax (Arm 2), and ruxolitinib (Arm 3) for patients with relapsed/refractory IDH1-mutated myeloid malignancies with a co-signaling mutation.
- To quantify the composite complete remission rate (CRc; CR + CRh + CRi) in patients with relapsed/refractory IDH1-mutated myeloid malignancies with a co-signaling mutation treated with olutasidenib in combination with cladribine + LDAC ± venetoclax (Arm 1), gilteritinib ± venetoclax (Arm 2), and ruxolitinib (Arm3).
Secondary Objectives
- To determine overall survival (OS), event free survival (EFS), and duration of response (DOR) with olutasidenib in combination with a co-targeting chemotherapeutic agent.
- To determine the overall response rate (ORR; CR + CRh + CRi + MLFS + PR) of olutasidenib in combination with a co-targeting chemotherapeutic agent.
- To evaluate occurrence of measurable residual disease (MRD) negative status by multiparameter flow cytometry and molecular evaluation by polymerase chain reaction (PCR) and next generation sequencing (NGS)-based assays (e.g. IDH1 and FLT3 if applicable).
- To characterize the pharmacokinetic (PK) profiles of olutasidenib and venetoclax in plasma samples.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years.
- •Participants with a diagnosis of relapsed and/or refractory AML (including biphenotypic or bilineage leukemia including a myeloid component) OR high-risk MDS, MPN, or MDS/MPN (defined as ≥10% blasts on peripheral flow cytometry or bone marrow biopsy).
- •Participants must have a documented IDH1 mutation.
- •Participants must also have a documented co-signaling mutation in one or more of the following: KRAS, NRAS, PTPN11, CBL, NF1, FLT3-ITD, FLT3-TKD, KIT, JAK2, MPL, CALR, CSF3R.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status ≤
- •Adequate renal function with estimated GFR ≥ 30 by the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).
- •Adequate hepatic function, defined as direct bilirubin ≤ 2x upper limit of normal (ULN) and AST and ALT ≤ 3x ULN unless the increase is due to Gilbert's disease or leukemic involvement, in which case direct bilirubin, AST, and ALT ≤ 5x ULN will be considered eligible.
- •The interval from prior treatment to time of initiation will be at least 14 days OR five half-lives for both cytotoxic and non-cytotoxic (e.g. immunotherapy agent(s)). Oral hydroxyurea and/or cytarabine (up to 2g/m2) is allowed for participants with rapidly proliferative disease prior tothe start and during the first two cycles of therapy, for clinical benefit and after discussion with the PI. Continuation of concurrent intrathecal therapy for controlled CNS disease is permitted.
- •Ability to understand and the willingness to sign an informed consent document.
排除标准
- •Participants who have received prior olutasidenib (Rezlidhiai, previously FT-2102).
- •Participants with translocation t(15;17) or acute promyelocytic leukemia (French-American British (FAB) class M3-AML).
- •Participants with any concurrent uncontrolled clinically significant medical condition, including life threatening infection, which could place the patient at unacceptable risk of study treatment.
- •Participants with any uncontrolled psychiatric illness that would limit compliance with study requirements.
- •Participants with a New York Heart Association (NYHA) Functional Classification of III or IV.
- •Participants with active graft-versus-host-disease (GVHD) status post stem cell transplant (Participants without active GVHD on phototherapy for chronic skin GVHD are permitted after discussion with the PI). Participants must have discontinued calcineurin inhibitors at least 4 weeks prior to the start of study treatment.
- •Participants with active, uncontrolled CNS leukemia.
- •Participants with any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications.
- •Known active hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV) infection. For participants with evidence of chronic HBV or HIV infection, the HBV or HIV viral load must be undetectable, respectively. For participants with a history of HCV, it must be treated and cured with an undetectable HCV viral load.
- •Participant has white blood cell count >25 x 109/L (Note: Hydroxyurea and cytarabine are permitted to mean this criterion).
- •The effects of the study drug on the developing human fetus or transmission through breast feeding are unknown. Therefore, nursing women and women with a positive urine pregnancy test and excluded. Additionally, women of child-bearing potential (WOCBP) and men who are sexually active with WOCBP who are not willing to maintain adequate contraception are excluded.
- •a. WOCBP includes all female participants between the onset of menses (as early as 8 years of age) to 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following: i. Postmenopausal (no menses in greater than or equal to 12 consecutive months).
- •ii. History of hysterectomy or bilateral salpingo-oophorectomy. iii. Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
- •iv. History of bilateral tubal ligation or another surgical sterilization procedure.
- •b. Approved methods of birth control are as follows: hormonal contraception (i.e. birth control pills, injection, transdermal patch, vaginal ring, hormonal implant), intrauterine device (IUD), tubal ligation or hysterectomy, subject/partner post-vasectomy, double barrier methods (e.g. condom in combination with spermicide). Abstinence for the duration of the trial and drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform the treating physician immediately.
- •c. Adequate contraception must be maintained from initiation of the study drug until 90 days after the last dose of the study drug.
- •History of an allergic reaction to venetoclax, gilteritinib, ruxolitinib, cladribine, or cytarabine.
研究组 & 干预措施
Arm 1A Safety Lead-In/Expansion:
Experimental
Treatment with Olutasidenib + Cladribine + Cytarabine
干预措施: Cladribine (CLAD) (Drug)
Arm 1B Expansion
Experimental
Treatment with Olutasidenib + Cladribine + Cytarabine + Venetoclax
干预措施: Olutasidenib (Drug)
Arm 1B Expansion
Experimental
Treatment with Olutasidenib + Cladribine + Cytarabine + Venetoclax
干预措施: Cladribine (CLAD) (Drug)
Arm 1A Safety Lead-In/Expansion:
Experimental
Treatment with Olutasidenib + Cladribine + Cytarabine
干预措施: Olutasidenib (Drug)
Arm 3A Safety Lead-In/Expansion:
Experimental
Treatment with Olutasidenib + Ruxolitinib
干预措施: Olutasidenib (Drug)
Arm 2A Safety Lead-In/Expansion
Experimental
Treatment with Olutasidenib + Gilteritnib
干预措施: Olutasidenib (Drug)
Arm 2A Safety Lead-In/Expansion
Experimental
Treatment with Olutasidenib + Gilteritnib
干预措施: Gilteritinib (Drug)
Arm 1A Safety Lead-In/Expansion:
Experimental
Treatment with Olutasidenib + Cladribine + Cytarabine
干预措施: Cytarabine (Drug)
Arm 1B Expansion
Experimental
Treatment with Olutasidenib + Cladribine + Cytarabine + Venetoclax
干预措施: Venetoclax (Drug)
Arm 1B Expansion
Experimental
Treatment with Olutasidenib + Cladribine + Cytarabine + Venetoclax
干预措施: Cytarabine (Drug)
Arm 2B Expansion
Experimental
Treatment with Olutasidenib + Gilteritnib + Venetoclax
干预措施: Gilteritinib (Drug)
Arm 2B Expansion
Experimental
Treatment with Olutasidenib + Gilteritnib + Venetoclax
干预措施: Olutasidenib (Drug)
Arm 2B Expansion
Experimental
Treatment with Olutasidenib + Gilteritnib + Venetoclax
干预措施: Venetoclax (Drug)
Arm 3A Safety Lead-In/Expansion:
Experimental
Treatment with Olutasidenib + Ruxolitinib
干预措施: Ruxolitinib (Drug)
结局指标
主要结局
Safety and adverse events (AEs)
时间窗: Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple MyelomaMultiple MyelomaNCT02718833Massachusetts General Hospital52
尚未招募
2 期
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric JunctionImmunotherapy Gastroesophageal JunctionNCT06396585Fujian Cancer Hospital28
已完成
3 期
Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract SymptomsLower Urinary Tract SymptomsBenign Prostatic HyperplasiaNCT01021332Astellas Pharma Europe B.V.1,067
招募中
不适用
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local TherapyMarginal Zone LymphomaNCT06478472The First Affiliated Hospital of Xiamen University36
撤回
2 期
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid TumorsEwing's SarcomaOsteosarcomaMedulloblastomaNeuroectodermal TumorWilms TumorGliomaRhabdomyosarcomaEpendymomaNCT02689336Washington University School of Medicine